ASMB
Assembly Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.60
+1.30%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
6282.2x
Market Cap
$745.20M
MomentumView details →
1D Return
+1.30%
YTD Return
+6.88%
RSI (14)
68.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
6282.2x
Market Cap
$745.20M
RSI (14)
68.0
MomentumView details →
1D Return
+1.30%
YTD Return
+6.88%
SummaryUpdated Jun 1, 2026
Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotechnology company founded in 2005 and headquartered in South San Francisco, California. Originally incorporated as Ventrus Biosciences, the company changed its name to Assembly Biosciences in June 2014. The company went public in December 2010 and focuses exclusively on developing therapeutic treatments for hepatitis B virus (HBV) infection, a serious liver disease that affects hundreds of millions of people worldwide.
Similar companies
Latest newsMore news →
Assembly Biosciences reported a Q2 2026 loss of $0.20 per share, beating the Zacks Consensus Estimate of a $0.70 loss and improving from a $1.33 loss a year earlier.22d agoAssembly Biosciences, Inc. elected Anthony E. Altig, Tomas Cihlar, Gina Consylman, Robert D. Cook II, and Sir Michael Houghton as directors effective June 4, 2026.92d ago